Ultragenyx Pharmaceutical RARE Liabilities For Sales Of Future Royalties Current
Liabilities For Sales Of Future Royalties Current at other companies
Other financials
Where this comes from
Reported directly by Ultragenyx Pharmaceutical in its filing.
Tagged under the XBRL concept rare:LiabilitiesForSalesOfFutureRoyaltiesCurrent.
The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ultragenyx Pharmaceutical's liabilities for sales of future royalties current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ultragenyx Pharmaceutical's liabilities for sales of future royalties current?
- Ultragenyx Pharmaceutical (RARE) reported liabilities for sales of future royalties current of $72M in Q1 2026.
- How has Ultragenyx Pharmaceutical's liabilities for sales of future royalties current changed year-over-year?
- Ultragenyx Pharmaceutical's liabilities for sales of future royalties current increased by 25.5% year-over-year, from $57.38M to $72M.
- What does liabilities for sales of future royalties current mean?
- This represents the portion of obligations arising from the monetization of future royalty streams that is due within the next twelve months. It reflects the company's commitment to pay out future revenue generated from specific products or intellectual property to third-party investors. Managing this liability is critical for assessing short-term cash flow obligations and the impact of non-dilutive financing arrangements on near-term liquidity.